AMOEBA (EPA:ALMIB) - AMOEBA announces that it has reached the last phase of the assessment for its regulatory dossier in the United States.

Transparency directive : regulatory news

12/09/2018 18:13

PRESS RELEASE

AMOEBA announces that it has reached the last phase of the assessment for its
regulatory dossier in the United States.

Lyon (France), September 12th, 2018 - AMOEBA (FR0011051598 - AMEBA), producer
of a biological biocide capable of eliminating the risk of waterborne bacteria,
announces the pursuit of its regulatory dossier assessment in the USA.

The dossier is now in its final phase of evaluation: "last science review". In
this process, Amoéba had technical exchanges with EPA (Environmental
Protection Agency) experts.

The end of the "last science review" is contingent on the submission of
confirmatory data requested by the EPA, that will be communicated by Amoéba to
the EPA in October 2018. This submission should lead to a shift in the
regulatory decision date, from the end of 2018 as initially planned, to the
first quarter of 2019.

"The exchanges with the EPA experts were constructive and have enabled to
precisely know their expectations. These interactions have been a key element
for the confirmatory data preparation that will be submitted in a timely
manner" declares Fabrice PLASSON, Chairman of AMOEBA.

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. Created in 2010, based in Chassieu (Lyon, France) with a
subsidiary in Canada and in the United States, Amoéba is quoted on the
compartment C of Euronext Paris. The Company is a member of the BPIfrance
Excellence network and is eligible for the PEA-PME SME equity savings plan
setup. More information on www.amoeba- biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts :

Amoéba
Valérie FILIATRE
Directeur administratif et Financier
04 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Actifin
Ghislaine GASPARETTO
Communication financière
01 56 88 11 11
ggasparetto@actifin.fr

Disclaimer
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the reference
document of AMOEBA filed with the French Financial Markets Authority (Autorité
des Marchés Financiers) on April 27, 2018 (a copy of which is available on
www.amoeba-biocide.com). The forward-looking statements contained in this press
release are also subject to risks not yet known to AMOEBA or not currently
considered material by AMOEBA. The occurrence of all or part of such risks
could cause actual results, financial conditions, performance or achievements
of AMOEBA to be materially different from such forward-looking statements.

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - AMOEBA announces that it has reached the last phase of the assessment for its regulatory dossier in the United States.

Transparency directive : regulatory news

AMOEBA's latest news

Other stories